Ask AI
ProCE Banner Activity

CKM Care in Harmony: A Masterclass in Orchestrating Better CKM Outcomes in Primary Care

Slideset

As a primary care healthcare professional, it is essential to recognize and treat cardiovascular-kidney-metabolic (CKM) conditions early and to ensure positive patient outcomes. Use these slides to learn best practices for identifying CKM syndrome, assessing patients’ overall risk profile, counseling patients on the bidirectional relationship of these conditions, and developing individualized, evidence-based treatment plans for those with CKM syndrome.

Released: October 07, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This program is intended for family medicine physicians, nurse practitioners, and physician associates and other primary care healthcare professionals involved in the care of patients with CKM diseases.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients at elevated cardiovascular and kidney risk to support earlier, evidence-based risk stratification strategies in family medicine settings

  • Develop individualized, evidence-based treatment plans that incorporate cardio-renoprotective therapies to reduce CKM-related morbidity and mortality

  • Implement team-based and patient-centered care strategies to improve coordination, optimize adherence, and reduce progression of CKM-related complications

Financial Disclosures

Primary Author

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP: consultant/advisor/speaker: Abiomed/Johnson & Johnson, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Idorsia, Lilly, Medtronic, Merck, Novo Nordisk, Regeneron, Renovacor, Respicardia/Zoll, Roche, Salubris, Sanofi Aventis, scPharmaceuticals, Vasa, Vifor.

Jay H. Shubrook, DO, FAAFP, FACOFP: researcher: Abbott; consultant/advisor/speaker: Boehringer Ingelheim, Insulet, Novo Nordisk, Sanofi.

Chuck Vega, MD, FAAFP: consultant/advisor/speaker: Boehringer Ingelheim, Exact Sciences, GSK.

Carol H. Wysham, MD: consultant/advisor/speaker: Abbott Diabetes, Lilly, MannKind, Novo Nordisk; researcher: AbbVie, Bayer.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.